These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19140849)

  • 1. A case report of double-filtration plasmapheresis for the treatment of age-related macular degeneration.
    Yeh JH; Cheng CK; Chiu HC
    Ther Apher Dial; 2008 Dec; 12(6):500-4. PubMed ID: 19140849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter prospective, randomized, double-masked, placebo-controlled study of Rheopheresis to treat nonexudative age-related macular degeneration: interim analysis.
    Pulido JS;
    Trans Am Ophthalmol Soc; 2002; 100():85-106; discussion 106-7. PubMed ID: 12545682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) results.
    Pulido JS; Winters JL; Boyer D
    Trans Am Ophthalmol Soc; 2006; 104():221-31. PubMed ID: 17471343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes and mechanism of action for rheopheresis treatment of age-related macular degeneration (AMD).
    Pulido J; Sanders D; Winters JL; Klingel R
    J Clin Apher; 2005 Oct; 20(3):185-94. PubMed ID: 15892078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central serous chorioretinopathy.
    Marcuson J; Riley T
    Optometry; 2008 May; 79(5):241-51. PubMed ID: 18436164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective, randomized, controlled clinical study evaluating the efficacy of Rheopheresis for dry age-related macular degeneration. Dry AMD treatment with Rheopheresis Trial-ART.
    Koss MJ; Kurz P; Tsobanelis T; Lehmacher W; Fassbender C; Klingel R; Koch FH
    Graefes Arch Clin Exp Ophthalmol; 2009 Oct; 247(10):1297-306. PubMed ID: 19629514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical studies to implement Rheopheresis for age-related macular degeneration guided by evidence-based-medicine.
    Klingel R; Fassbender C; Fassbender T; Göhlen B
    Transfus Apher Sci; 2003 Aug; 29(1):71-84. PubMed ID: 12877897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative assessment of photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a multicenter study in Hyogo prefecture, Japan.
    Honda S; Imai H; Yamashiro K; Kurimoto Y; Kanamori-Matsui N; Kagotani Y; Tamura Y; Yamamoto H; Ohoto S; Takagi H; Uenishi M; Negi A
    Ophthalmologica; 2009; 223(5):333-8. PubMed ID: 19478533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions.
    Tsuchiya D; Yamamoto T; Kawasaki R; Yamashita H
    Retina; 2009; 29(7):960-5. PubMed ID: 19491727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Macular translocation with 360 retinectomy for submacular hemorrhage in age related macular degeneration].
    Stopa M; Kociecki J
    Klin Oczna; 2009; 111(1-3):50-5. PubMed ID: 19517847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RheoNet registry analysis of rheopheresis for microcirculatory disorders with a focus on age-related macular degeneration.
    Klingel R; Fassbender C; Heibges A; Koch F; Nasemann J; Engelmann K; Carl T; Meinke M; Erdtracht B
    Ther Apher Dial; 2010 Jun; 14(3):276-86. PubMed ID: 20609179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration.
    Hayashi H; Yamashiro K; Tsujikawa A; Ota M; Otani A; Yoshimura N
    Am J Ophthalmol; 2009 Jul; 148(1):83-9.e1. PubMed ID: 19327745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No evidence to support the use of plasmapheresis for age-related macular degeneration.
    Finger RP; Krohne TU; Charbel Issa P; Scholl HP; Holz FG
    Ther Apher Dial; 2010 Dec; 14(6):607-8; author reply 608-9. PubMed ID: 21118372
    [No Abstract]   [Full Text] [Related]  

  • 15. A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration.
    Newsome DA
    Curr Eye Res; 2008 Jul; 33(7):591-8. PubMed ID: 18600492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of optical density ratios in subretinal fluid as a clinically relevant biomarker in exudative macular disease.
    Ahlers C; Golbaz I; Einwallner E; Dunavölgyi R; Malamos P; Stock G; Pruente C; Schmidt-Erfurth U
    Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3417-24. PubMed ID: 19168899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration.
    Theodossiadis PG; Liarakos VS; Sfikakis PP; Vergados IA; Theodossiadis GP
    Am J Ophthalmol; 2009 May; 147(5):825-30, 830.e1. PubMed ID: 19211094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
    Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [ITAP - 6-month results of a prospective, randomised phase 3 study for evaluation of the combination therapy of PDT and intravitreal triamcinolone in exudative AMD].
    Gamulescu MA; Schubert K; Thormann S; Attaran M; Dueck N; Wiechens B; Spital G; Stroux A; Wachtlin J
    Klin Monbl Augenheilkd; 2009 Jan; 226(1):60-5. PubMed ID: 19173165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve-month safety and visual acuity results from a feasibility study of intraocular, epiretinal radiation therapy for the treatment of subfoveal CNV secondary to AMD.
    Avila MP; Farah ME; Santos A; Kapran Z; Duprat JP; Woodward BW; Nau J
    Retina; 2009 Feb; 29(2):157-69. PubMed ID: 19202425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.